| Sep 19 |
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
|
| Sep 17 |
Aethlon Medical to Present at Virtual Investor Conferences in September
|
| Sep 17 |
Innovation Driving Cancer's Solid Tumors Market
|
| Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
| Sep 16 |
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
|
| Sep 13 |
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
|
| Aug 27 |
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
|
| Aug 15 |
AEMD: Oncology Trial Advancing; Approval from 2nd Site
|
| Aug 14 |
Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript
|
| Aug 14 |
Aethlon Medical GAAP EPS of -$0.34 misses by $0.02
|
